200 related articles for article (PubMed ID: 29275106)
1. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
[TBL] [Abstract][Full Text] [Related]
2. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L
Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108
[TBL] [Abstract][Full Text] [Related]
4. PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
Yu Z; Song Y; Cai M; Jiang B; Zhang Z; Wang L; Jiang Y; Zou L; Liu X; Yu N; Mao X; Peng C; Liu S
Aging (Albany NY); 2021 Sep; 13(17):21294-21308. PubMed ID: 34470916
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
[TBL] [Abstract][Full Text] [Related]
6. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
[TBL] [Abstract][Full Text] [Related]
7. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
8. NF-κB-induced WIP1 expression promotes colorectal cancer cell proliferation through mTOR signaling.
Bai F; Zhou H; Fu Z; Xie J; Hu Y; Nie S
Biomed Pharmacother; 2018 Mar; 99():402-410. PubMed ID: 29367109
[TBL] [Abstract][Full Text] [Related]
9. PPM1D regulates p21 expression via dephoshporylation at serine 123.
Cao R; Zhang J; Zhang M; Chen X
Cell Cycle; 2015; 14(4):641-7. PubMed ID: 25590690
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of Wip1 overexpression and its association with the p38MAPK/p53/p16 pathway in NSCLC.
Yang S; Dong S; Qu X; Zhong X; Zhang Q
Mol Med Rep; 2017 Feb; 15(2):719-723. PubMed ID: 27959454
[TBL] [Abstract][Full Text] [Related]
11. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
13. p21
Lee J; Kim J; Kim EM; Kim U; Kang AR; Park JK; Um HD
Biochem Biophys Res Commun; 2021 Mar; 543():23-28. PubMed ID: 33503543
[TBL] [Abstract][Full Text] [Related]
14. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D.
Castellino RC; De Bortoli M; Lu X; Moon SH; Nguyen TA; Shepard MA; Rao PH; Donehower LA; Kim JY
J Neurooncol; 2008 Feb; 86(3):245-56. PubMed ID: 17932621
[TBL] [Abstract][Full Text] [Related]
15. Wip1 over-expression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas.
Wang P; Rao J; Yang H; Zhao H; Yang L
J Surg Oncol; 2011 Nov; 104(6):679-84. PubMed ID: 21695702
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
[TBL] [Abstract][Full Text] [Related]
17. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
Fuku T; Semba S; Yutori H; Yokozaki H
Pathol Int; 2007 Sep; 57(9):566-71. PubMed ID: 17685927
[TBL] [Abstract][Full Text] [Related]
18. Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
Lu ZW; Wen D; Wei WJ; Han LT; Xiang J; Wang YL; Wang Y; Liao T; Ji QH
Oncol Rep; 2020 Mar; 43(3):783-794. PubMed ID: 31922231
[TBL] [Abstract][Full Text] [Related]
19. Wip1 cooperates with KPNA2 to modulate the cell proliferation and migration of colorectal cancer via a p53-dependent manner.
Wang P; Zhao Y; Liu K; Liu X; Liang J; Zhou H; Wang Z; Zhou Z; Xu N
J Cell Biochem; 2019 Sep; 120(9):15709-15718. PubMed ID: 31127650
[TBL] [Abstract][Full Text] [Related]
20. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
Han HS; Yu E; Song JY; Park JY; Jang SJ; Choi J
Mol Cancer Res; 2009 May; 7(5):713-23. PubMed ID: 19435816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
